| Prospectus synopsis |
| |
|
|
Phone:91-079-68138700 Fax:
|
| Initial public offer of 20,925,652* equity shares of face value of Re. 1 each ("Equity Shares") of Concord Biotech Limited ("Company") for cash at a price of Rs. 741 per equity share (including a premium of Rs. 740 per equity share) ("Offer Price") aggregating to Rs. 1550.52*^ crores (the "Offer") through an offer for sale of 20,925,652* equity shares aggregating to
Rs. 1550.52*^ crores by Helix Investment Holdings Pte. Limited (the "Selling Shareholder") and such equity shares offered by the selling shareholder, the ("Offered Shares").
The offer includes a reservation of 10,000* equity shares, aggregating to
Rs. 0.67^ crores (constituting 0.01% of the post-offer paid-up equity share capital), for subscription by eligible employees ("Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as "Net Offer". The offer and net offer constitute 20% and 19.99%, of the post-offer paid-up equity share capital of the company, respectively. The face value of equity shares is Re. 1 each. The offer price is Rs. 741 times the face value.
*Subject to finalisation of basis of allotment.
^A discount of Rs. 70 per equity share was offered to eligible employees bidding in the employee reservation portion.
|
| 04-Aug-23 |
08-Aug-23 |
Rs
741.00-0.00
|
Rs
0.00-0.00
|
| Minimum Application for shares in Nos :
20
Further Multiples of :
20
|
| Project Cost |
0.00 |
| Citigroup Global Markets India Pvt Ltd |
| Kotak Mahindra Capital Company Ltd |
|
| Project Financed through Current Offer |
1550.52 |
|
| Post Issue Equity Share Capital |
10.46 |
|
| Issue Price |
Rs.741.00
|
|
|
|